301211 Hubei Biocause Heilen Pharmaceutical
- 16.40
- +0.03+0.18%
Hubei Biocause Heilen Pharmaceutical News
Hendy Pharmaceuticals (301211.SZ) plans to pay 4.8 yuan for 10 shares to be deducted from interest on May 27
Hendy Pharmaceuticals (301211.SZ) announced that the company's 2023 profit distribution will be distributed to all shareholders for every 10 shares...
Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation
Hubei Biocause Heilen Pharmaceutical's (SHE:301211) torsemide tablets passed the generic drug quality and efficacy consistency evaluation of China's National Medical Products Administration, the comp
Hendy Pharmaceuticals (301211.SZ): Torasemide tablets pass generic drug consistency evaluation
Gelonghui, May 16 | Hendi Pharmaceutical (301211.SZ) announced that the company recently received the “Drug Supplement Application Approval Notice” for torasemide tablets (hereinafter referred to as “drugs”) approved and issued by the State Drug Administration. The company's torasemide tablets are cardiovascular drugs, mainly used for edema associated with high blood pressure, chronic congestive heart failure, liver cirrhosis, ascites, and nephrotic syndrome.
Hendy Pharmaceuticals (301211.SZ): Currently not involved in the field of synthetic biology
Gelonghui, May 6 | Hendi Pharmaceutical (301211.SZ) said on the investor interactive platform that the company is mainly engaged in R&D, production and sales of chemical raw materials (including intermediates) and pharmaceutical products, and can also provide contract R&D and production services (CDMO) according to customer needs. Contract R&D and production services (CDMO) include intermediates, key starting materials, and APIs to meet the needs of customers for process R&D, pilot scale-up, commercial production, method verification and registration at all stages from pre-clinical to commercialization. The company is currently not involved in the field of synthetic biology.
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something co
Hendy Pharmaceuticals (301211.SZ) announced first-quarter results, net profit of 37.3816 million yuan, a decrease of 6.37%
Hendy Pharmaceuticals (301211.SZ) released its report for the first quarter of 2024, achieving operating income of 1.3 during the reporting period...
Hendy Pharmaceutical (301211.SZ): Obtained CEP certificate for cladribine API
Gelonghui, April 23 | Hengdi Pharmaceutical (301211.SZ) announced that recently, Hubei Hengdi Pharmaceutical Co., Ltd. received the European Pharmacopeia Suitability Certificate for APIs (“CEP Certificate”) issued by the European Medicines Quality Administration. Cladribine has tumor suppressive activity. It is mainly passively transported into cells, phosphorylated by deoxycytidine kinase in cells, converted into cladribine triphosphate, and blended into DNA molecules, which interferes with the repair effect of DNA after DNA breakage, causing depletion of NAD and ATP, disrupting cellular metabolism, and affecting cellular DNA synthesis. The commonly used dosage form is an injection, used through interferon
Hendy Pharmaceuticals (301211.SZ) announced its 2023 annual results, with net profit of 176 million yuan, an increase of 40.00%
Hendy Pharmaceuticals (301211.SZ) released its 2023 annual report. The company's revenue was 663 million yuan...
Hendy Pharmaceuticals (301211.SZ): As of February 29, 2024, the number of shareholders of the company was 2,3060
Gelonghui March 4 | Hendi Pharmaceutical (301211.SZ) said on an interactive platform that as of February 29, 2024, the number of shareholders of the company was 23,060.
Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Market Cap Dropped CN¥524m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Hubei Biocause Heilen Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions
Hendy Pharmaceuticals (301211.SZ): As of December 20, 2023, the number of shareholders of the company was 25,601
Gelonghui January 3 | Hendi Pharmaceutical (301211.SZ) said on an interactive platform that as of December 20, 2023, the number of shareholders of the company was 25,601.
Hendy Pharmaceutical (301211.SZ): The ban on 2.797 million restricted shares will be lifted on December 22
Glonghui December 19丨Hendy Pharmaceutical (301211.SZ) announced an indicative announcement on the listing and circulation of some restricted shares in the initial public offering. The shareholder applying to lift the share sale restrictions this time was Guotai Junan Zhengyu Investment Co., Ltd., and the number of shares lifted was 2,796.97 million shares, accounting for 0.969% of the company's total share capital. The starting date for lifting the restrictions on the sale of shares is December 22, 2021. The sale restriction period is 24 months from the date of listing of the company's shares, and the listing and circulation date is December 22, 2023.
Is COVID-19 making a comeback? The new strain JN.1 spread rapidly in 12 countries around the world, and the concept of virus prevention and control is booming across the board
Expert: No need to worry
Should Weakness in Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) recent performance, when its stock has declined 7.1% over the past week. But if you pay close attentio
[Instant Analysis of BT Financial Report] Hendi Pharmaceutical's 2023 Third Quarter Report: Net assets and net profit have increased significantly, and performance has risen steadily
Announcement time of this financial report: 2023-10-17 16:58:55 Hendy Pharmaceutical (stock code: 301211) is a company focusing on R&D, production and sales of chemical raw materials and pharmaceutical products. The company has deep accumulation in the pharmaceutical manufacturing industry, mainly covering the manufacture of chemical raw materials and the manufacture of chemical pharmaceutical preparations. According to its 2023 three-quarter report, we can see that the company is growing steadily in all financial data. First, judging from the balance and liability situation, Hendy Pharmaceutical's net assets reached 2,327 billion yuan at the end of this reporting period, compared to 22 at the end of the previous year
Hendi Pharmaceutical (301211.SZ): Net profit of 145 million yuan in the first three quarters increased 83.98% year-on-year
Glonghui, October 17: Hendy Pharmaceutical (301211.SZ) announced its third quarter report. Revenue was 542 million yuan, up 56.93% year on year, net profit was 145 million yuan, up 83.98% year on year, after deducting non-net profit of 140 million yuan, up 96.40% year on year, and basic earnings per share were 0.50 yuan.
Private Companies Among Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 5.7% Last Week
Key Insights Hubei Biocause Heilen Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 2 shareholde
Hendi Pharmaceutical (301211.SZ) issued a forecast increase. Net profit for the first three quarters is expected to reach 130 million yuan to 160 million yuan, an increase of 65.5% to 103.69%
Hendy Pharmaceutical (301211.SZ) disclosed its performance forecast for the third quarter of 2023. The company expects the first three quarters to belong...
Hendy Pharmaceutical (301211.SZ): Net profit increased 107.80% in the first half of the year to 113 million yuan
Glonghui, August 24 | Hendy Pharmaceutical (301211.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 406 million yuan, up 68.80% year on year; net profit attributable to shareholders of listed companies was 113 million yuan, up 107.80% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 110 million yuan, up 117.76% year on year; basic earnings per share were 0.39 yuan.
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Investors Are up 7.4% in the Past Week, but Earnings Have Declined Over the Last Year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio)
Analysis
Price Target
No Data
